Activation of β2- and β3-adrenergic receptors increases brain tryptophan

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 653-659

  Lenard, Natalie R ^a   Gettys, Thomas W ^b   Dunn, Adrian J ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 HYDROXYINDOLEACETIC ACID; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRANOLOL; CLENBUTEROL; DOBUTAMINE; PROPRANOLOL; SEROTONIN; TRYPTOPHAN; ETHANOLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DISSECTION; DRUG EFFECT; DRUG RECEPTOR BINDING; ELECTROCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INJECTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; ANIMAL; BIOSYNTHESIS; BRAIN LEVEL; DRUG POTENTIATION; GENETICS; KINETICS; METABOLISM; MOUSE MUTANT;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BRAIN CHEMISTRY; DOBUTAMINE; ETHANOLAMINES; KINETICS; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; SEROTONIN; TRYPTOPHAN;

EID: 0037946847     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.048249     Document Type: Article

References (49)

1. 3-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440:99-107.
2. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, and Wilson S (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (Lond) 309:163-165.
3. 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol 298:287-292.
4. Banks WA, Clever CM, and Farrell CL (2000) Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am J Physiol Endocrinol Metab 278:E1158-E1165.
5. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, and Shakhar K (2000) Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and β-adrenoceptors. Neuroimmunomodulation 8:154-164.
6. Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, Dolan JA, and Claus TH (1992) Disodium (R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent β-adrenergic agonist virtually specific for β3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 35:3081-3084.
7. Carswell H and Nahorski SR (1983) β-Adrenoceptor heterogeneity in guinea-pig airways: comparison of functional and receptor labelling studies. Br J Pharmacol 79:965-971.
8. Chaouloff F, Elghozi JL, Guezennec Y, and Laude D (1985) Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5-hydroxytryptamine metabolism of the rat. Br J Pharmacol 86:33-41.
9. 3-adrenoceptor agonist SR58611A inhibits gastric acid secretion in the conscious cat. Naunyn Schmiedebergs Arch Pharmacol 356:263-265.
10. Crissman AM, Makhay MM, and O'Donnell JM (2001) Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by β-1 adrenergic receptors. Psychopharmacology (Berl) 154:70-75.
11. Curzon G (1979) Relationships between plasma, CSF and brain tryptophan. J Neural Transm 15 (Suppl):81-92.
12. Curzon G, Joseph MH, and Knott PJ (1972) Effects of immobilization and food deprivation on rat brain tryptophan metabolism. J Neurochem 19:1967-1974.
13. Dunn AJ (1988a) Changes in plasma and brain tryptophan and brain serotonin and 5-hydroxyindoleacetic acid after footshock stress. Life Sci 42:1847-1853.
14. Dunn AJ (1988b) Stress-related changes in cerebral catecholamine and indoleamine metabolism: lack of effect of adrenalectomy and corticosterone. J Neurochem 51:406-412.
15. Dunn AJ (1993) Neurochemical methods for evaluating cerebral biogenic amine responses to cytokines and their involvement in the central actions of interleukin-1, in Neurobiology of Cytokines (De Souza EB ed) pp 209-222, Academic Press, Inc., San Diego, CA.
16. Dunn AJ and Welch J (1991) Stress- and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend on sympathetic nervous system activity. J Neurochem 57:1615-1622.
17. Edwards DJ and Sorisio DA (1988) Effects of imipramine on tyrosine and tryptophan are mediated by β-adrenoceptor stimulation. Life Sci 42:853-862.
18. Edwards DJ, Sorisio DA, and Knopf S (1989) Effects of the β2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem Pharmacol 38:2957-2965.
19. Edwards DJ and Virji MA (1990) Hypoaminoacidemia caused by imipramine but not clenbuterol is dissociable from hyperglycemia and hyperinsulinemia. Life Sci 47:PL13-PL18.
20. Engel G, Maurer R, Perrot K, and Richardson BP (1985) β-Adrenoceptor subtypes in sections of rat and guinea pig kidney. Naunyn Schmiedebergs Arch Pharmacol 328:354-357.
21. Eriksson T and Carlsson A (1988) β-adrenergic control of brain uptake of large neutral amino acids. Life Sci 42:1583-1589.
22. Evans BA, Agar L, and Summers RJ (1999) The role of the sympathetic nervous system in the regulation of leptin synthesis in C57BL/6 mice. FEBS Lett 444:149-154.
23. Evans BA, Papaioannou M, Bonazzi VR, and Summers RJ (1996) Expression of β3-adrenoceptor mRNA in rat tissues. Br J Pharmacol 117:210-216.
24. Fernstrom JD (1976) The effect of nutritional factors on brain amino acid levels and monoamine synthesis. Fed Proc 35:1151-1156.
25. Fernstrom JD (1983) Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 63:484-546.
26. Fernstrom JD and Wurtman RJ (1972) Brain serotonin content: physiological regulation by plasma neutral amino acids. Science (Wash DC) 178:414-416.
27. Guillaume JL, Petitjean F, Haasemann M, Bianchi C, Eshdat Y, and Strosberg AD (1994) Antibodies for the immunochemistry of the human β3-adrenergic receptor. Eur J Biochem 224:761-770.
28. Jacobs BL and Fornal CA (1999) Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 21 (Suppl):9S-15S.
29. Jensen J, Brors O, and Dahl HA (1995) Different adrenergic receptor density in different rat skeletal muscle fibre types. Pharmacol Toxicol 76:380-385.
30. Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T, Giudice A, Guzzi U, Landi M, and Le Fur G (1996) Functional identification of rat atypical β-adrenoceptors by the first β3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117:435-442.
31. McPherson GA, Malta E, Molenaar P, and Raper C (1984) The affinity and efficacy of the selective beta 1-adrenoceptor stimulant RO363 at β1- and β2-adrenoceptor sites. Br J Pharmacol 82:897-904.
32. Minneman KP, Hegstrand LR, and Molinoff PB (1979) Simultaneous determination of β-1 and β-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 16:34-36.
33. Muruganandam A, Herx LM, Monette R, Durkin JP, and Stanimirovic D (1997) Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. FASEB J 11:1187-1197.
34. 3-adrenoceptors. Trends Pharmacol Sci 18:257-258.
35. O'Donnell SR and Wanstall JC (1985) Responses to the β2-selective agonist procaterol of vascular and atrial preparations with different functional β-adrenoceptor populations. Br J Pharmacol 84:227-235.
36. Rueter LE, Fornal CA, and Jacobs BL (1997) A critical review of 5-HT brain microdialysis and behavior. Rev Neurosci 8:117-137.
37. Ruffolo RR Jr (1987) The pharmacology of dobutamine. Am J Med Sci 294:244-248.
38. Sakura H, Togashi M, and Iwamoto Y (2002) β3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs. Nippon Rinsho 60:123-129.
39. Schiff AA and Saxey A (1984) Autoradiography of nadolol and propranolol in the rat. Xenobiotica 14:687-691.
40. Soeder KJ, Snedden SK, Cao W, Della Rocca GJ, Daniel KW, Luttrell LM, and Collins S (1999) The β3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem 274:12017-12022.
41. Summers RJ, Papaioannou M, Harris S, and Evans BA (1995) Expression of β3-adrenoceptor mRNA in rat brain. Br J Pharmacol 116:2547-2548.
42. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME, Himms-Hagen J, Flier JS, and Lowell BB (1995) Targeted disruption of the β3-adrenergic receptor gene. J Biol Chem 270:29483-29492.
43. Takao Y, Kamisaki Y, and Itoh T (1992) β-Adrenergic regulation of amine precursor amino acid transport across the blood-brain barrier. Eur J Pharmacol 215:245-251.
44. Williams RS and Bishop T (1981) Selectivity of dobutamine for adrenergic receptor subtypes. J Clin Invest 67:1703-1711.
45. Wurtman RJ and Fernstrom JD (1976) Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochem Pharmacol 25:1691-1696.
46. Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, and Lakatta EG (1999) Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84:43-52.
47. + channel-independent pathway of glucose signaling in rat pancreatic islets. Diabetes 48:1006-1012.
48. Yang XM and Dunn AJ (1990) Central beta 1-adrenergic receptors are involved in CRF-induced defensive withdrawal. Pharmacol Biochem Behav 36:847-851.
49. Zhang YC, Bui JD, Shen L, and Phillips MI (2000) Antisense inhibition of beta-1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 101:682-688.